Stock ADAG ADAGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Adagene Inc.

Equities

ADAG

US0053291078

Market Closed - Nasdaq
Other stock markets
 21:30:00 29/05/2024 BST 		5-day change 1st Jan Change
2.64 USD +4.35% Intraday chart for Adagene Inc. +1.15% +36.69%
03-29 Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-29 Adagene Inc. Announces Board Changes CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Adagene to Present at Investor Conferences in June
GL
Adagene : Entry into Sales Agreement - Form 6-K
PU
Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
GL
Adagene Inc. Announces Board Changes
CI
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
GL
Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board
CI
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
GL
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
AQ
ADRs Close Higher, Ambow Education Holding Ltd. Climbs 117.4%
DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
MT
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination
MT
Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody
CI
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
GL
ADRs End Higher; The9 Climbs 16%
DJ
Adagene Reports Positive Data on Colorectal Cancer Treatment Combination
MT
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
GL
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
AQ
Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium
CI
ADRs End Lower; Aslan Pharmaceuticals Declines 38%
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADAG Stock
  4. News Adagene Inc.